{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:40:42Z","timestamp":1789688442201,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.brainres.2009.05.004","type":"journal-article","created":{"date-parts":[[2009,5,10]],"date-time":"2009-05-10T04:16:30Z","timestamp":1241928990000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors"],"prefix":"10.1016","volume":"1279","author":[{"given":"Shinsui","family":"Kunitachi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamaki","family":"Ishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanibuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiko","family":"Shirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2009.05.004_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.pnpbp.2008.08.001","article-title":"A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia","volume":"32","author":"Akhondzadeh","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib2","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1471-4159.2007.05047.x","article-title":"Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat","volume":"104","author":"Anastasio","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.brainres.2009.05.004_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1254\/jphs.CRJ04005X","article-title":"The role of sigma receptors in depression","volume":"97","author":"Bermack","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.brainres.2009.05.004_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.brainres.2009.05.004_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0920-9964(01)00387-5","article-title":"An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia","volume":"59","author":"Buchanan","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.brainres.2009.05.004_bib6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/15622970701432551","article-title":"Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial","volume":"10","author":"Chung","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10673229609017192","article-title":"The glutamatergic dysfunction hypothesis for schizophrenia","volume":"3","author":"Coyle","year":"1996","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2009.05.004_bib9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/sj.npp.1300761","article-title":"Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice","volume":"30","author":"Csernansky","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2009.05.004_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.WNF.0000240940.67241.F6","article-title":"Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study","volume":"30","author":"Fagerlund","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib11","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMra035458","article-title":"Schizophrenia","volume":"349","author":"Freedman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.brainres.2009.05.004_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00213-005-2235-1","article-title":"Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial","volume":"181","author":"Freudenreich","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2009.05.004_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-004-1794-x","article-title":"Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists","volume":"174","author":"Friedman","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2009.05.004_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-3223(01)01342-7","article-title":"A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia","volume":"51","author":"Friedman","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.06.023","article-title":"Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria","volume":"56","author":"Green","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00213-004-1920-9","article-title":"Sigma receptors: biology and therapeutic potential","volume":"174","author":"Guitart","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.brainres.2009.05.004_bib17","unstructured":"Hashimoto, K., in press. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. CNS Agents Med. Chem."},{"key":"10.1016\/j.brainres.2009.05.004_bib18","series-title":"Sigma Receptors","first-page":"225","article-title":"Imaging sigma receptors and cerebral responses to sigma drugs","author":"Hashimoto","year":"1994"},{"key":"10.1016\/j.brainres.2009.05.004_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0014-2999(94)00763-W","article-title":"Interactions of erythro-ifenprodil, threo-ifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors","volume":"273","author":"Hashimoto","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib20","first-page":"3857","article-title":"Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals","volume":"12","author":"Hashimoto","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.brainres.2009.05.004_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archpsyc.60.6.572","article-title":"Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia","volume":"60","author":"Hashimoto","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib22","first-page":"147","article-title":"Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs","volume":"4","author":"Hashimoto","year":"2004","journal-title":"Curr. Med. Chem-CNS.Agents"},{"key":"10.1016\/j.brainres.2009.05.004_bib23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2005.07.002","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol","volume":"519","author":"Hashimoto","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2174\/1573400054065569","article-title":"Dysfunction of glia-neuron communication in pathophysiology of schizophrenia","volume":"1","author":"Hashimoto","year":"2005","journal-title":"Curr. Psychiatry Rev."},{"key":"10.1016\/j.brainres.2009.05.004_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors","volume":"32","author":"Hashimoto","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2009.05.004_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biopsych.2007.04.034","article-title":"Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective \u03b17 nicotinic receptor agonist SSR180711","volume":"63","author":"Hashimoto","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00023210-200418050-00001","article-title":"Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders","volume":"18","author":"Hayashi","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.brainres.2009.05.004_bib28","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.brainres.2009.05.004_bib29","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/S0014-2999(96)00702-9","article-title":"Decrease in \u03c3 but no increase in striatal dopamine D4 sites in schizophrenic brains","volume":"314","author":"Helmeste","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib30","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","article-title":"High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503","volume":"62","author":"Ishikawa","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib31","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.pnpbp.2008.06.011","article-title":"Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors","volume":"32","author":"Ishima","year":"2008","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874241600902010007","article-title":"Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline","volume":"2","author":"Ishima","year":"2009","journal-title":"Open. Clin. Chem. J."},{"key":"10.1016\/j.brainres.2009.05.004_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03026824","article-title":"A feasibility study of [11C]SA4503-PET for evaluating sigma-l receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors","volume":"20","author":"Ishiwata","year":"2006","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.brainres.2009.05.004_bib34","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.pnpbp.2008.01.005","article-title":"Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia","volume":"32","author":"Iyo","year":"2008","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.npp.1300313","article-title":"Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-d-aspartate receptor\/glycine-site agonists","volume":"29","author":"Javitt","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2009.05.004_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2009.05.004_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3940(98)00943-4","article-title":"TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons","volume":"260","author":"Kato","year":"1999","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.brainres.2009.05.004_bib39","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.npp.1301499","article-title":"Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo\/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial","volume":"33","author":"Keefe","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2009.05.004_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/hrp\/7.3.125","article-title":"NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders","volume":"7","author":"Krystal","year":"1999","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.schres.2004.07.005","article-title":"Neurocognitive impairment across the lifespan in schizophrenia: an update","volume":"74","author":"Kurtz","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.brainres.2009.05.004_bib42","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.0001-690X.2001.acp1c008d.x","article-title":"Donepezil in schizophrenia\u2014is it helpful? An experimental design case study","volume":"104","author":"MacEwan","year":"2001","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.brainres.2009.05.004_bib43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00008877-200311000-00006","article-title":"Repeated administration of phencyclidine, amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits","volume":"14","author":"Mandillo","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1385\/JMN:17:2:205","article-title":"Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits","volume":"17","author":"Mattson","year":"2001","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.brainres.2009.05.004_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0165-0173(01)00112-6","article-title":"The interaction between neuroactive steroids and the sigma-1 receptor function: behavioral consequences and therapeutic opportunities","volume":"37","author":"Maurice","year":"2001","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.brainres.2009.05.004_bib46","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/jpet.105.097394","article-title":"Interaction with sigma-1 protein, but not N-methyl-d-aspartate receptor, is involved in the pharmacological activity of donepezil","volume":"317","author":"Maurice","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2009.05.004_bib47","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/jpet.106.101527","article-title":"Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas","volume":"317","author":"Meunier","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2009.05.004_bib48","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","article-title":"The anti-amnesic and neuroprotective effects of donepezil against amyloid-\u03b225\u201335 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor","volume":"149","author":"Meunier","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1254\/jphs.CR0050032","article-title":"The sigma-1 protein as a target for the non-genomic effects of neuro(active)steroids: molecular, physiological, and behavioral aspects","volume":"100","author":"Monnet","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.brainres.2009.05.004_bib50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/47513","article-title":"Caspase-12 mediated ebdoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta","volume":"403","author":"Nakagawa","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.brainres.2009.05.004_bib51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","article-title":"Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain","volume":"307","author":"Narita","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib52","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1527-3458.1996.tb00299.x","article-title":"NE-100: a novel sigma receptor antagonist","volume":"2","author":"Okuyama","year":"1996","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.brainres.2009.05.004_bib53","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archpsyc.1995.03950240016004","article-title":"Glutamate receptor dysfunction and schizophrenia","volume":"52","author":"Olney","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.brainres.2009.05.004_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/neucas\/7.2.105","article-title":"A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates","volume":"7","author":"Risch","year":"2001","journal-title":"Neurocase"},{"key":"10.1016\/j.brainres.2009.05.004_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.schres.2007.01.001","article-title":"Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study","volume":"93","author":"Risch","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.brainres.2009.05.004_bib56","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14656566.8.7.1011","article-title":"Donepezil: an update","volume":"8","author":"Seltzer","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.brainres.2009.05.004_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0031-9384(96)00447-7","article-title":"Reduction of the scopolamine-induced impairment of passive-avoidance performance by sigma receptor agonist in mice","volume":"61","author":"Senda","year":"1997","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.brainres.2009.05.004_bib58","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF00966825","article-title":"Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication","volume":"17","author":"Shibuya","year":"1992","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.brainres.2009.05.004_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0920-9964(91)90019-N","article-title":"Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication","volume":"6","author":"Simpson","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.brainres.2009.05.004_bib60","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.2174\/0929867033456783","article-title":"Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction","volume":"10","author":"Su","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.brainres.2009.05.004_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1017\/S1461145703004024","article-title":"A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia","volume":"7","author":"Tugal","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.brainres.2009.05.004_bib62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0006-3223(91)90209-5","article-title":"Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia","volume":"29","author":"Weissman","year":"1991","journal-title":"Biol. Psychiatry"}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899309009342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006899309009342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T17:39:09Z","timestamp":1757785149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006899309009342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":62,"alternative-id":["S0006899309009342"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2009.05.004","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors","name":"articletitle","label":"Article Title"},{"value":"Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brainres.2009.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}